Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05335434 · ClinicalTrials.gov registry record · NA
Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation
A NA study of Oral Mucositis and Myeloablative Allogeneic Hematopoietic Cell Transplantation, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05335434: Recruiting NA study of Oral Mucositis and Myeloablative Allogeneic Hematopoietic Cell Transplantation, sponsored by Dana-Farber Cancer Institute.
NCT05335434 is a NA study of Oral Mucositis and Myeloablative Allogeneic Hematopoietic Cell Transplantation that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 20 participants, below the 106-participant average among 10 other Oral Mucositis trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05335434, a NA study of Oral Mucositis and Myeloablative Allogeneic Hematopoietic Cell Transplantation, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). Patients who are planned for alloHCT will receive daily intraoral photobiomodulation therapy (PBMT) using a novel LED device. The name of the study device involved in this study is: \- THOR LX2.3 with LED Lollipop
Primary Outcome
Defined as the total number of days between day 0 and day +20 on which severe (WHO grade 3 or 4) OM was reported
Conditions Studied
Interventions
- DEVICE THOR LX2.3 with LED Lollipop
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-06-10 |
| Est. Completion | 2026-07-19 |
| Phase | NA |
What NCT05335434 shows while recruiting
NCT05335434 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 106-participant average among 10 other Oral Mucositis trials with a reported enrollment target (81% lower).
The record links to 4 conditions, with Oral Mucositis appearing as the primary indexed condition, and to 1 intervention - of which THOR LX2.3 with LED Lollipop is the first listed.
NCT05335434 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05335434 about?
NCT05335434 is a clinical study titled "Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation". This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). Patients who are planned for alloHCT will receive daily intraoral photobiomodulation therapy ...
What is the current status of trial NCT05335434?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2022-06-10. Estimated completion is 2026-07-19.
What conditions does trial NCT05335434 study?
This clinical trial studies the following conditions: Oral Mucositis, Myeloablative Allogeneic Hematopoietic Cell Transplantation, Intraoral Photobiomodulation Therapy, Mucosal Ulcer.
What interventions are being tested in trial NCT05335434?
The interventions under investigation include: THOR LX2.3 with LED Lollipop (DEVICE).
Who is sponsoring clinical trial NCT05335434?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05335434 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oral Mucositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05335434's enrollment target sits among peer trials
20 10th of 10 higher than 1 of 10 other Oral Mucositis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Oral Mucositis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors)
RECRUITING · NA
-
Prevention of Oral Mucositis Using Photobiomodulation Therapy
COMPLETED · NA
-
Coconut Oil to Prevent Mouth Sores in Pediatric Patients Receiving High Dose Chemotherapy
RECRUITING · Phase 2
-
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
RECRUITING · Phase 2
-
Photobiomodulation for the Prevention of Oral Mucositis
ACTIVE NOT RECRUITING · Phase 2
-
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI